Method of retarding the progression of chronic renal failure

Details Method of retarding the progression of chronic renal failure Method of retarding the progression of chronic renal failure

1995-07-03

1997-01-07

Henley, III, Raymond

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

A61K 3156

Patent

active

055917364

ABSTRACT:
The progression of chronic renal failure in humans may be retarded by administration of dehydroepiandrosterone (DHEA) in effective amounts. The administration of DHEA is preferably oral at a dose of about 400 to 1600 mg/day. Patients suffering from severe chronic renal failure are also preferably maintained on a protein-restricted diet during DHEA administration.

REFERENCES:
patent: 4100160 (1978-07-01), Walser
patent: 4228099 (1980-10-01), Walser
patent: 4352814 (1982-10-01), Walser
patent: 4496556 (1985-01-01), Orentreich
patent: 4542129 (1985-09-01), Orentreich
patent: 4752619 (1988-06-01), Walser et al.
patent: 5175144 (1992-12-01), Walser
Abstract (Accession Number QD586-0004) of Araneo et al., "Dehydropepiandrosterone Functions as More than an Antiglucocorticoid in Preserving Immunocompetence after Thermal Injury" Endocrinology 136(2): 393-401 (Feb. 1995).
Kalimi et al., "Anti-Glucocorticoid Effects of Dehydroepiandrosterone (DHEA)", Mol. Cell. Biochem. 131:99-104 (1994).
Lucas et al., "Prevention of Autoantibody Formation and Prolonged Survival in New Zealand Black/New Zealand White F.sub.1 Mice Fed Dehydroisoandrosterone", J. Clin. Invest. 75:2091-2093 (1995).
McIntosh et al., "Strain Differences in the Dose-Response Curves of Adrenalectomized, Starved-Refed Rats to Dehydroepiandrosterone (DHEA) (42657)", Proc. Soc. Exp. Biol. Med. 187:216-222 (1988).
Meikle et al., "The Presence of a Dehydroepiandrosterone-Specific Receptor Binding Complex in Murine T Cells", J. Steroid Biochem. Molec. Biol. 42(3/4):293-304 (1992).
Meikle et al., "Adrenal Androgen Secretion and Biologic Effects", Endrocinol. Metab. Clinics N. Amer. 20(2):381-400 (1991).
Pashko et al., "Inhibition of Proteinuria Development in Aging Sprague-Dawley Rats and C57BL/6 Mice by Long-Term Treatment with Dehydroepiandrosterone", J. Gerontol. 41(4):433-438 (1986).
Suzuki et al., "Dehydroepiandrosterone Enhances IL2 Production and Cytotoxic Effector Function of Human T Cells", Clin. Immunol. Immunopath. 61:202-211 (1991).
Svec et al., "The Effect of DHEA Given Chronically to Zucker Rats (43883)", Proc. Soc. Exp. Biol. Med. 209:92-97 (1995).
van Vollenhoven et al., "An Open Study of Dehydroepiandrosterone in Systemic Lupus Erythematosus", Arthritis Rheum. 37(9): 1305-1310 (1994).
Walser et al., "Progression of Chronic Renal Failure is Related to Glucocorticoid Production", Kidney Int. 34:859-866 (1988).
Walser et al., "Progression of Chronic Renal Failure in Patients Given Ketoacids Following Amino Acids", Kidney Int. 32:123-128 (1987).
Winer et al., "Preservation of Normal Adrenal Androgen Secretion in End Stage Renal Disease", Metabolism 31(3):269-273 (1982).
Zumoff et al., "Subnormal Plasma Adrenal Androgen Levels in Men with Uremia", J. Clin. Endocrin. Metab. 51(4):801-805 (1980).

Affiliated with

Also associated with

Rating

Method of retarding the progression of chronic renal failure does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of retarding the progression of chronic renal failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of retarding the progression of chronic renal failure will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1764297